JERSEY, Channel Islands, Jan. 21, 2020 -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal third.
If you own shares in Quotient Limited (NASDAQ:QTNT) then it's worth thinking about how it contributes to the...
Quotient Limited (QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland, today announced that it has received the Conformité Européene (CE) Mark approval for the Initial Serological Disease Screening (SDS) Microarray. This is our third market clearance and the CE certification of our second Microarray within a year marks an important leap forward for our Company as we continue to expand both our Serological Disease Screening and Immunohematology (IH) menus.
Investors who take an interest in Quotient Limited (NASDAQ:QTNT) should definitely note that the Chairman of the...
Quotient (QTNT) delivered earnings and revenue surprises of 9.76% and 11.85%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Quotient Limited (QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland, today reported positive performance data for its SARS-CoV-2 antibody test. Based on these results, under applicable regulations, the Company can now offer the MosaiQ COVID-19 Antibody Microarray as a research-use-only (RUO) product in Europe and the US.
Quotient Limited (QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland, today announced the Company will host an investor information conference call and live webcast on March 25, 2020 at 8:00 am Eastern Time. To maintain an ongoing flow of information with investors and analysts, we have decided to offer a virtual information conference call and live webcast on Wednesday, March 25, 2020 at 8:00 a.m. Eastern Time. Participants may access the call by dialing 1-877-407-0784 in the U.S. or 1-201-689-8560 outside the U.S. The access code is 13700421.
Quotient (QTNT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Quotient Limited (NASDAQ:QTNT) shares fell 6.8% to US$7.46 in the week since its latest quarterly results. The...
Quotient Limited (QTNT), a commercial-stage diagnostics company, headquartered in Eysins, Switzerland, and hVIVO, part of Open Orphan plc (ORPH.L), today announced that the MosaiQ™ by Quotient system and MosaiQ COVID-19 Antibody Microarray will be used by hVIVO to screen for SARS-CoV-2 antibodies (COVID-19). Quotient has entered into an exclusive contract with hVIVO, whereby Quotient is hVIVO's exclusive supplier of COVID-19 antibody testing equipment, to support COVID-19 antibody testing in the UK.
Quotient Limited (QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland, today announced that it has completed the process for declaring conformity to the essential requirements of the In Vitro Diagnostics Directive (IVDD 98/79/EC) and has CE marked (Conformité Européene) its SARS-CoV-2 (COVID-19) antibody microarray. The test is now available for sale in Europe and Switzerland. The MosaiQ COVID-19 Antibody Microarray is designed as a serological disease screen specific to COVID-19.
JERSEY, Channel Islands, May 26, 2020 -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal fourth.
JERSEY, Channel Islands, Feb. 24, 2020 -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland, today.
Quotient (QTNT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
JERSEY, Channel Islands, May 26, 2020 -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced the Company will present at the Jefferies.
Molecular Disease Screening Microarray Feasibility Study CompletedInitial Serological Disease Screening FDA 510(k) Submission AcceptedCommencement of EU Expanded.
Quotient has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
JERSEY, Channel Islands, April 27, 2020 -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland, today.
Quotient Limited (QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland, today announced the completion of the development phase of a microarray based SARS-CoV-2 (COVID-19) antibody test for the fully automated high throughput MosaiQ system in response to the global COVID-19 pandemic. The development phase is now complete, and the manufacturing process has been initiated at our facility in Eysins, Switzerland.
Q3 2020 Quotient Ltd Earnings Call